
Evermine 50 EES-1 study

Study Highlights

- Principal Investigator: Dr. K. Sivaprasad
- Evermine 50[™] EES-1 is a prospective, postmarketing, multi-center, study to evaluate safety and performance of ultrathin strut biodegradable polymer-coated with everolimus-eluting coronary stent (EES) in patients with coronary artery disease
- Safety and performance endpoints of the stent will be evaluated till 2 years
- The study demonstrated favourable safety and performance of ultra-thin biodegradable polymer EES with ultrathin strut thickness for treatment of coronary artery disease



Study Design

A prospective, multicentre, post-marketing study



A total of 114 patients were enrolled



9 investigational sites across India



Clinical follow-up for 1-month and 9-months and Telephonic/clinical follow-up for 6-month, 12-month and 24-month



Angiographic follow-up at 9 months

Analysed by CBCC Global Research LLP, Ahmedabad, India



OCT follow-up at 6 months

Analysed by CBCC Global Research LLP, Ahmedabad, India

Study Results




Figure 1: Summary of diseased vessel in patients treated with Evermine 50 EES, (%)




Figure 2: Cardiac status of patients treated with Evermine 50 EES, (%)

QCA Analysis




Figure 3: Late lumen loss at 9-month follow-up

***** References

1. Clinical Trial number [CTRI/2017/02/007781]

http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16395&EncHid=&userName=CTRI/2017/02/007781

- 2. K. Sivaprasad et al. Initial Experience With Ultrathin Strut Biodegradable Polymer-Coated Everolimus-Eluting Coronary Stent in Coronary Artery Disease Patients. Journal of the American College of Cardiology. 2018, 72(13). Supplement/B220.2.
- 3. K. Sivaprasad, One-Year Clinical Outcomes of World's Thinnest (50 µm) Biodegradable Polymer-Coated Everolimus-Eluting Coronary Stent in Patients with Coronary Artery Disease. TCT 2019. (25-30 September)
- 4. K. Sivaprasad, Clinical outcomes of world's thinnest (50 μ m) biodegradable polymer-coated everolimus-eluting coronary stent system in patients with coronary artery disease. EuroPCR 2020 (19-22 May).